Reuters logo
BRIEF-U.S. FDA says investigation into an ImprimisRx product highlights some risks
August 4, 2017 / 7:22 PM / 2 months ago

BRIEF-U.S. FDA says investigation into an ImprimisRx product highlights some risks

Aug 4 (Reuters) - U.S. Food & Drug Administration:

* U.S. FDA investigation into two serious adverse events associated with ImprimisRx’s compounded curcumin emulsion product for injection

* Says on June 23, 2017, ImprimisRx recalled all unexpired products containing the ungraded PEG 40 castor oil​

* Investigation into adverse events associated with ImprimisRx’s curcumin emulsion product highlights some risks related to compounded drugs‍​

* Risks associated with curcumin emulsion product include absence of label warning about hypersensitivity reactions associated with the PEG 40 castor oil Source text: (bit.ly/2ffFqwY) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below